Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease.
Antiparkinson Agents
/ pharmacology
Apoptosis
/ drug effects
Apoptosis Regulatory Proteins
/ metabolism
Caffeic Acids
/ pharmacology
Cell Line, Tumor
Humans
Membrane Potential, Mitochondrial
/ drug effects
Neurons
/ drug effects
Neuroprotective Agents
/ pharmacology
Oxidative Stress
/ drug effects
Oxidopamine
/ toxicity
Parkinson Disease
/ drug therapy
Phenylethyl Alcohol
/ analogs & derivatives
Reactive Oxygen Species
/ metabolism
Signal Transduction
6-Hydroxydopamine (6-OHDA)
Apoptosis
Caffeic acid phenethyl ester (CAPE)
Neuroprotection
Parkinson's disease
SH-SY5Y cells
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
15 Sep 2020
15 Sep 2020
Historique:
received:
28
01
2020
revised:
26
06
2020
accepted:
29
06
2020
pubmed:
8
7
2020
medline:
19
5
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, and oxidative stress and mitochondrial dysfunction play a major role in the pathogenesis of PD. Since conventional therapeutics are not sufficient for the treatment of PD, the development of new agents with anti-oxidant potential is crucial. Caffeic Acid Phenethyl Ester (CAPE), a biologically active flavonoid of propolis, possesses several biological properties such as immunomodulatory, anti-inflammatory and anti-oxidative. In the present study, we investigated the neuroprotective effects of CAPE against 6-hydroxydopamine (6-OHDA)-induced SH-SY5Y cells. The neuroprotective effects were detected by using cell viability, Annexin V, Hoechst staining, total caspase activity, cell cycle, as well as western blotting. Besides, the anti-oxidative activity was measured by the production of reactive oxygen species and mitochondrial function was determined by measurement of mitochondrial membrane potential (ΔΨm). We found that CAPE significantly increased cell viability and decreased apoptotic cell death (~20%) after 150 μM 6-OHDA exposure following 24 h. 1.25 μM CAPE also prevented 6-OHDA-induced changes in condensed nuclear morphology. Furthermore, treatment with 1.25 μM CAPE increased mitochondrial membrane potential in 6-OHDA-exposed cells. CAPE inhibited 6-OHDA-induced caspase activity (~2 fold) and production of reactive oxygen species. In addition, 150 μM 6-OHDA-induced down-regulation of Bcl-2 and Akt levels and up-regulation of Bax and cleaved caspase-9/caspase-9 levels were partially restored by 1.25 μM CAPE treatment. These results revealed a neuroprotective potential of CAPE against 6-OHDA-induced apoptosis in an in vitro PD model and may be a potential therapeutic candidate for the prevention of neurodegeneration in Parkinson's Disease.
Identifiants
pubmed: 32634439
pii: S0014-2999(20)30434-9
doi: 10.1016/j.ejphar.2020.173342
pii:
doi:
Substances chimiques
Antiparkinson Agents
0
Apoptosis Regulatory Proteins
0
Caffeic Acids
0
Neuroprotective Agents
0
Reactive Oxygen Species
0
Oxidopamine
8HW4YBZ748
caffeic acid phenethyl ester
G960R9S5SK
Phenylethyl Alcohol
ML9LGA7468
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173342Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.